[N/A Former Name if Applicable 4/F Building B Chuangye Square, No. 48 Keji Road Gaoxin District, Xi’an, Shaanxi Province, P.R. China City, State and Zip Code PART II -- RULES 12b-25(b) AND (c) x (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; (b) The subject annual]
[N/A Former Name if Applicable 4/F Building B Chuangye Square, No. 48 Keji Road Gaoxin District, Xi’an, Shaanxi Province, P.R. China City, State and Zip Code PART II -- RULES 12b-25(b) AND (c) x (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; (b) The subject annual]
[SKYSTAR BIO-PHARMACEUTICAL COMPANY ANNOUNCES RECEIPT OF NASDAQ NON-COMPLIANCE LETTER DUE TO DELAY IN FILING FORM 10-K Xi’an, China, April 15, 2015 – Skystar Bio-Pharmaceutical Company (Nasdaq: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that the Company received a notification from the Nasdaq Stock Market (“Nasdaq”) informing the Company that since it] [805 King Farm Blvd. Rockville, MD 20850 / USA Nasdaq.com By Electronic Delivery to: bing@skystarbio-pharmaceutical.com; aorudjev@schiffhardin.com; scramer@skystarbio-pharmaceutical.com April 15, 2015 Mr. Bing Mei Chief Financial Officer Skystar Bio-Pharmaceutical Company 4/F Building B, Chuangye Square, No. 48 Keji Road Gaoxin District, Xi’an Shaanxi Province, P.R. China Re: Skystar Bio-Pharmaceutical Company (the “Company”) Nasdaq Symbol: SKBI Dear Mr. Mei: 1 I am] []
[SCHEDULE 13D (Amendment No. 04 )* SKYSTAR BIO-PHARMACEUTICAL CO (Name of Issuer) Common Stock (Title of Class of Securities) 830884102 (CUSIP Number) John M. Gregory, SJ Strategic Investments, LLC 340 MARTIN LUTHER KING, JR. BLVD., Suite 200 BRISTOL, Tennessee 37620 Phone : (423) 989-8133 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) December 10, 2014]
[SCHEDULE 13D (Amendment No. 04 )* SKYSTAR BIO-PHARMACEUTICAL CO (Name of Issuer) Common Stock (Title of Class of Securities) 830884102 (CUSIP Number) John M. Gregory, SJ Strategic Investments, LLC 340 MARTIN LUTHER KING, JR. BLVD., Suite 200 BRISTOL, Tennessee 37620 Phone : (423) 989-8133 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) December 10, 2014]
[] [EMPLOYMENT AGREEMENT Agreement Executive Company This EMPLOYMENT AGREEMENT (this “ WHEREAS, the Company desires to employ Executive as its Chief Financial Officer on the terms and conditions as set forth hereinafter, and Executive desires to be so employed; NOW, THEREFORE, IN CONSIDERATION of the foregoing facts, the mutual covenants and agreements contained herein and other good and valuable consideration, the] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. November 14, 2014 Weibing Lu Chief Executive Officer] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. November 14, 2014 Bing Mei Chief Financial Officer]
